Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 192 |
| Active Pipeline (Recruiting Now) | 87 (48) |
| Completed vs Stopped Early | 52 / 51 (26.6%) |
| Median Closed Actual Enrollment | 34 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Washington University and Siteman Cancer Center | Saint Louis, MO | 158 |
| University of Washington | Seattle, WA | 5 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06647498 | A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation | Phase II/III | RECRUITING |
| NCT05552157 | A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation | Phase II/III | RECRUITING |
| NCT05269394 | Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Indiv | Phase II/III | ACTIVE NOT RECRUITING |
| NCT03735979 | Multi-arm Optimization of Stroke Thrombolysis | Phase III | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the Washington University School of Medicine Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.